| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8993761 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 8 days ago) | |
| US8399469 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA PHARM CO LTD | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 8 months ago) | |
| US8338428 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(a month ago) | |
| US8759351 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Aug, 2023
(a month ago) | |
| US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 16 days from now) | |
| US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 16 days from now) | |
| US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(1 year, 16 days from now) | |
| US8338427 | OTSUKA PHARM CO LTD | Methods for administering aripiprazole |
Mar, 2025
(1 year, 5 months from now) | |
| US11400087 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US10980803 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11154553 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US11344547 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Sep, 2033
(9 years from now) | |
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(10 years from now) | |
| US11648347 | OTSUKA PHARM CO LTD | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient |
Apr, 2034
(10 years from now) | |
Abilify Maintena Kit is owned by Otsuka Pharm Co Ltd.
Abilify Maintena Kit contains Aripiprazole.
Abilify Maintena Kit has a total of 15 drug patents out of which 4 drug patents have expired.
Expired drug patents of Abilify Maintena Kit are:
- US9089567
- US8338428
- US8759351
- US8993761
Abilify Maintena Kit was authorised for market use on 28 February, 2013.
Abilify Maintena Kit is available in for suspension, extended release;intramuscular dosage forms.
Abilify Maintena Kit can be used as maintenance monotherapy treatment of bipolar i disorder; treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia, treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia, treatment of schizophrenia; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia, use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; treatment of schizophrenia, treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; maintenance monotherapy treatment of bipolar i disorder; treatment of schizophrenia, treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia; maintenance monotherapy treatment of bipolar i disorder, maintenance monotherapy treatment of bipolar 1 disorder; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia, treatment of schizophrenia, use of aripiprazole in extended release injectable suspension; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia.
The generics of Abilify Maintena Kit are possible to be released after 06 April, 2034.
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Use of aripiprazole in extended release injectable suspension; Tr...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic